Unlocking the Potential of Therapy-Induced Cytokine Responses: Illuminating New Pathways in Cancer Precision Medicine.

Precision cancer medicine primarily aims to identify individual patient genomic variations and exploit vulnerabilities in cancer cells to select suitable patients for specific drugs. These genomic features are commonly determined by gene sequencing prior to therapy, to identify individuals who would be most responsive. This precision approach in cancer therapeutics remains a powerful tool that benefits a smaller pool of patients, sparing others from unnecessary treatments. A limitation of this approach is that proteins, not genes, are the ultimate effectors of biological functions, and therefore the targets of therapeutics. An additional dimension in precision medicine that considers an individual's cytokine response to cancer therapeutics is proposed. Cytokine responses to therapy are multifactorial and vary among individuals. Thus, precision is dictated by the nature and magnitude of cytokine responses in the tumor microenvironment exposed to therapy. This review highlights cytokine responses as modules for precision medicine in cancer therapy, including potential challenges. For solid tumors, both detectability of cytokines in tissue fluids and their being amenable to routine sensitive analyses could address the difficulty of specimen collection for diagnosis and monitoring. Therefore, in precision cancer medicine, cytokines offer rational targets that can be utilized to enhance the efficacy of cancer therapy.

Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD-L1 and MHC I in colon cancer cells.

Topoisomerase inhibitors are clinically used to treat various cancer types, including colorectal cancer. These drugs also activate signaling pathways that modulate cell survival and immune cell functions. Immunotherapy is promising for certain tumors, including microsatellite instable colorectal cancer, but not for microsatellite stable colorectal cancer. The reasons for this lack of responsiveness are largely unknown. Understanding how colorectal cancer cell-surface proteins interact with tumor-resident immune cells may offer an opportunity to identify molecules that, if targeted, may render tumor cells visible to immune cells. The present study used flow cytometry, fluorescent staining and immunoblotting to examine if inhibition of pathways activated by topoisomerase-targeting drugs may modulate the outcomes of treatment through effects on cell cycle arrest and apoptosis, and by altering surface expression levels of programmed death-ligand 1 (PD-L1) or major histocompatibility complex protein I (MHC I). Inhibition of either NF-κB or DNA-damage response (DDR) potently enhanced cell death in combination with topoisomerase inhibition, while only NF-κB inhibition increased MHC I. PD-L1 upregulation was moderately affected by NF-κB or DDR inhibitors, while both topoisomerase inhibitors and DNA damaging agents may enhance the surface expression of MHC I molecules on colon cancer cells. Such enhanced expression of MHC I may be suppressed by inhibitors of ataxia-telangiectasia mutated or checkpoint kinase kinases. Additionally, adaptive tolerance to topoisomerase inhibition caused altered cell cycle response, and reduced the expression levels of both PD-L1 and MHC I on both microsatellite instable and stable colon cancer cell lines. Therefore, targeted modulation of DDR pathways, PD-L1, MHC I or other immune regulators in colon cancer cells may make them more visible to immune cells and enable rational combination of conventional therapy with immunotherapy.

Influence of Fish Scale-Based Hydroxyapatite on Forcespun Polycaprolactone Fiber Scaffolds.

Marine waste byproducts, especially fish scales, have proved to be one of the most prominent sources for developing sustainable materials for various applications including biomedical applications. Hydroxyapatite (HAp), being one of such biomaterials that can be synthesized from the massive fish-based waste, has received plentitude of attention due to its excellent ability to promote cell growth and proliferation. However, understanding the influence of HAp on polymer matrices that are tailored for biomedical applications is still a challenge. This study is intended to develop a sophisticated yet inexpensive method to obtain nonwoven polycaprolactone (PCL) nanofibrous scaffolds and analyze the influence of calcium-deficient nanoporous hydroxyapatite (n-HAp) on the thermal, mechanical, and biological properties of these scaffolds. The n-HAp is synthesized using two different types of fish scales, carpa (CA) and pink perch (PP), by calcination followed by nanomilling. The synthesized n-HAp powder is characterized by using X-ray diffraction, scanning electron microscopy (SEM), transmission electron microscopy (TEM), and X-ray photoelectron spectroscopy. The PCL fibrous scaffolds were developed using a novel forcespinning technique with n-HAp as the filler. The morphology of the scaffolds was characterized using SEM and Raman spectroscopy. SEM and TEM results have confirmed the size reduction of the HAp powder after nanomilling. Thermal properties were analyzed using thermogravimetric analysis and differential scanning calorimetry. The major degradation temperature has increased by 3° and was observed to be 398° for 1 wt % filler loading for both carpa and pink perch-derived n-HAp. The increase in filler content has increased the residue left after decomposition and is 4% for 5 wt % filler loading. The crystallinity percent has increased by 7% compared to neat fibers for 1 wt % filler loading. Mechanical properties were tested using tensile tests. The tensile test strength has shown 32% improvement for 1 wt % compared to neat fibers. Cell viability tests were performed using hFOB cells which have shown significant cell growth for a high filler loading of 5 wt %. The results suggest that both CA-n-HAP and PP-n-Hap-incorporated fibrous scaffolds can be used potentially for biomedical applications after careful investigation of the scaffold behavior with longer incubation periods.